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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

SOCIAL NETWORKING IN THE AGE OF PERSONAL GENOMICS
SANDRA SOO-JIN LEE*
The beginning of the 21st century has ushered in a much-heralded era
of personal genomics that presents new challenges to the regulation of
human genetic testing. Personal genomics builds upon human genetic
variation research—the area of study that attempts to identify how genetic
differences may be associated with the onset of disease or the expression of
a human trait or condition.1 Based upon initial results from genome-wide
association studies, dozens of companies now offer “personalized” genetic
tests for a widening range of complex conditions and traits, including, for
example, the analysis of genetic ancestry, or the determination of relative
risk for developing, for example, colon cancer.2 Many within the scientific
community have joined an active debate over the validity and utility of
personal genomics for the individual consumer, with some expressing
skepticism over the potential public health benefits of personal genomics.3

* Sandra Soo-Jin Lee, Ph.D., is a medical anthropologist and Senior Research Scholar at the
Center for Biomedical Ethics at Stanford University Medical School. Funding for this article
was provided by a grant from the National Human Genome Research Institute, National
Institutes of Health (P50 #HG003389). Dr. Lee would like to thank the participants at the
Saint Louis University Health Law Symposium, “Living in the Genetic Age: New Issues, New
Challenges,” for their helpful comments and suggestions on the presentation on which this
article is based.
1. See Elizabeth Pennisi, Breakthrough of the Year: Human Genetic Variation, 318
SCIENCE 1842, 1842 (2007). See also Jocelyn Kaiser, It’s All About Me, 318 SCIENCE 1843,
1843 (2007).
2. Sarah E. Gollust et al., Direct-to-Consumer Sales of Genetic Services on the Internet,
5 GENETICS MED. 332, 333 (2003); Katrina A.B. Goddard et al., Awareness and Use of
Direct-to-Consumer Nutrigenomic Tests, United States, 2006, 9 GENETICS MED. 510, 510
(2007).
3. See, e.g., Deborah A. Bolnick et al., The Science and Business of Genetic Ancestry
Testing, 318 SCIENCE 399, 399-400 (explaining that genetic ancestry tests often provide
information about only a few of the customer’s ancestors); Wylie Burke, Genetic Testing, 347
NEW ENG. J. MED. 1867, 1871-72 (2002) (noting that because some disorders may have
different causes, testing for all possible mutations may be prohibitively expensive); Sarah E.
Gollust et al., Limitations to Direct-to-Consumer Advertising for Clinical Genetic Testing, 288
JAMA 1762, 1762-63 (2002) (arguing for increased regulation of advertisements for genetic
tests); David J. Hunter et al., Letting the Genome Out of the Bottle – Will We Get Our Wish?,
358 NEW ENG. J. MED. 105, 106 (2008) (explaining that “even very small error rates per SNP,
41
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Whether personal genomics will ultimately improve health outcomes
remains to be seen, yet what is disturbingly clear is that the current
infrastructure of regulation has not kept pace with capitalization of emerging
technology for personal genetic services and products. As personal
genomic testing is introduced to and taken up by the public, it is imperative
to consider and anticipate long-term ethical concerns over genetic testing.
It is equally important to consider novel uses of personal genomics that may
include purposes outside of the realm of clinical issues as they may prove
critical to the creation of new regulatory guidelines aimed at protecting both
commercial innovation and public health.
Since the completion of the Human Genome Project, the unexpected
precipitous decline in the cost of genetic sequencing has resulted in a
proliferation of companies which now market products and services that
The
provide personal genetic information directly to consumers.4
development of increasingly efficient high-throughput genetic sequencing
technologies in concert with ubiquitous Internet use by the public has laid
the foundation for these commercial developments.5 This combination of
factors may foreshadow several paradigm shifts in how the public consumes
personal genetic information.
The direct-to-consumer (DTC) marketplace articulates these shifts as
stemming from changes in public desire for personal genomics.6 The first of
magnified across the genome, can result in hundreds of misclassified variants for any
individual patient”); Linda L. McCabe & Edward R.B. McCabe, Direct-to-Consumer Genetic
Testing: Access and Marketing, 6 GENETICS MED. 58, 58-59 (2004) (explaining that
consumers are not able to adequately analyze direct-to-consumer marketing); Roxanne
Mykitiuk, Caveat Emptor: Direct-to-Consumer Supply and Advertising of Genetic Testing, 27
CLINICAL & INVESTIGATIVE MED. 23, 25-26 (2004) (noting how the misunderstanding of genetic
information can lead to improper and unhealthy lifestyle adjustments); Christopher H. Wade &
Benjamin S. Wilfond, Ethical and Clinical Practice Considerations for Genetic Counselors
Related to Direct-to-Consumer Marketing of Genetic Tests, 142C AM. J. MED. GENETICS 284,
285-86 (2006) (noting that “the literature on risk factors for common diseases is often
inconsistent due to the publication of gene-disease associations that turn out to be spurious”);
Adam J. Wolfberg, Genes on the Web – Direct-to-Consumer Marketing of Genetic Testing,
355 NEW ENG. J. MED. 543, 543-44 (2006) (noting critics’ concern that the companies are
exploiting consumers’ anxiety in order to sell them unnecessary tests).
4. See Kaiser, supra note 1, at 1843. See also Gollust et al., supra note 3, at 1762.
5. See generally, Gollust et al., supra note 2, at 332 (discussing the availability of directto-consumer genetic services); Mykitiuk, supra note 3, at 23 (discussing issues of direct-toconsumer genetic tests in Canada).
6. Amy L. McGuire et al., Social Networkers’ Attitudes Toward Direct-to-Consumer
Personal Genome Testing, AM. J. BIOETHICS, June 2009, at 3, 4-5 (noting that sixty-four
percent of respondents to a survey “indicated that they would consider using [personal
genome tests] in the future” and that forty percent of respondents found personal genome tests
appealing because they can “learn about their genetic make-up without having to go through
a physician”).
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these claims is that knowledge of a person’s genetic code is “empowering”
and will enable individuals to make better decisions about lifestyle, health,
and medical care.7 The second is that a new era of “openness” challenges
traditional approaches to genetic testing, requiring a different ethical
framework towards public protection.8 This position suggests a new attitude
towards personal information and individual privacy. And, the third claim
argues that in a context where large population-based DNA collections are
needed to fuel genomic research, industry will play a critical role in scalingup the collection of genotypic and phenotypic information needed for large
cohort genetic studies.9 Although these predictions have yet to be validated
as only time will tell, it is imperative to consider what questions these
putative shifts may generate in anticipating effective and timely regulation of
the capitalization of emerging genomic technologies.
I. THE RISE OF DTC PERSONAL GENOMICS
Two years after the company 23andMe, Inc. launched in 2006,10 Time
Magazine named 23andMe’s DNA-testing service “Time’s 2008 Invention
of the Year.”11 Anita Hamilton, an author for Time Magazine wrote, “We
are [only] at the beginning of a personal-genomics[sic] revolution that will
transform not only how we take care of ourselves but also what we mean by
personal information.”12 The California-based 23andMe, which was
founded by Linda Avey and Anne Wojcicki, has become a leader in a
burgeoning industry aimed at offering genetic testing directly to consumers
over the Internet.13 Funded by Google, Inc., Genentech, Inc., and New

7. See Bryn Williams-Jones, ‘Be Ready Against Cancer, Now’: Direct-to-Consumer
Advertising for Genetic Testing, 25 NEW GENETICS & SOC’Y 89, 91 (2006).
8. See generally Katherine Wasson et al., Direct-to-Consumer Online Genetic Testing
and the Four Principles: An Analysis of the Ethical Issues, 22 ETHICS & MED. 83, 83, 90 (2006)
(discussing how uncertainty regarding the accuracy and reliability of direct-to-consumer
genetic tests raises moral and ethical considerations). See also Williams-Jones, supra note 7,
at 89 (discussing “[t]he social, ethical and policy implications of the commercialization of
genetic testing for health related [sic] conditions . . .”).
9. See Henry T. Greely, The Uneasy Ethical and Legal Underpinnings of Large-Scale
Genomic Biobanks, 8 ANN. REV. GENOMICS & HUM. GENETICS 343, 344-49 (2007).
10. 23andMe, Inc., 23andMe, Inc. Fact Sheet [hereinafter 23andMe, Inc. Fact Sheet],
https://23andme.https.internapcdn.net/res/4843/pdf/factsheet.pdf (last visited Jan. 09,
2010).
11. Anita Hamilton, TIME’s Best Inventions of 2008, TIME, Oct. 29, 2008,
http://www.time.com/time/specials/packages/article/0,28804,1852747_1854493,00.html.
12. Id.
13. 23andMe, Inc. Fact Sheet, supra note 10.
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Enterprise Associates, 23andMe is emblematic of a growing category of
companies that actively seek to make genetic testing ubiquitous.14
Under the heading “Genetics Just Got Personal,”15 23andMe offers tests
that reveal patterns of hundreds of thousands of single-nucleotide
polymorphisms (SNPs) across an individual’s genome.16 23andMe tests for
over 600,000 SNPs through the Illumina HumanHap 550+ BeadChip17
and makes the results—both the raw data and their analyses—available to
customers through a password-protected website.18 The company offers two
main categories of products: a genetic ancestry edition, and a health
edition.19 The company provides several portals through which to interpret
genetic results, including an application where customers learn about their
SNP patterns (genotypes) and their associations with different ethnic
populations.20
23andMe is similar to other companies, including Bay area neighbor
Navigenics, Inc. and the Icelandic company deCODE genetics.21 These
companies use the same sequencing technology to offer similar tests,22
though they distinguish themselves by price and test offerings. In contrast to
23andMe’s current fee of $399 (the lowest in the current market),
Navigenics charges its customers $999 for individualized information on
genetic risk for twenty-eight different complex diseases and syndromes, and
promises to update customers with new information as genomic research
advances.23 Navigenics “believe[s] that [it] can fundamentally improve
14. 23andMe, Inc., 23andMe Corporate Info, https://www.23andme.com/about/
corporate/ (last visited Jan. 09, 2010).
15. 23andMe, Inc., Home Page, https://www.23andme.com (last visited Jan. 09, 2010).
16. 23andMe, Inc., Frequently Asked Questions, How Does 23andMe Genotype My
DNA?, https://www.23andme.com/you/faqwin/chip/ (last visited Jan. 09, 2010).
17. 23andMe, Inc., Genotyping Technology, https://www.23andme.com/more/geno
typing/ (last visited Jan. 09, 2010).
18. 23andMe, Inc., Help FAQ, Who Can Access My Account?, https://www.23and
me.com/you/faqwin/accountaccess/ (last visited Jan. 09, 2010).
19. See 23andMe, Inc., Store [hereinafter 23andMe Store], https://www.23andme.com/
store/ (last visited Jan. 09, 2010).
20. 23andMe, Inc., Help FAQ, What does the Odds Calculator Show?, https://www.23
andme.com/you/faqwin/whatisincidence/ (last visited Jan. 09, 2010).
21. See Navigenics, Inc., Home Page, http://www.navigenics.com (last visited Jan. 09,
2010); deCODE genetics, Home Page, http://www.decode.com (last visited Jan. 09, 2010).
22. Like 23andME, Navigenics and deCODE genetics both offer single nucleotide
polymorphism (SNP) genotyping. See 23andMe, Inc., Help FAQ, How Does 23andMe
Genotype My Data?, https://www.23andme.com/you/faqwin/chip/ (last visited Jan. 09,
2010); deCODE genetics, Scientific Services, http://www.decode.com/genotyping/index.php
(last visited Jan. 09, 2010); Navigenics, Inc., The Science Behind the Navigenics Service,
http://www.navigenics.com/static/pdf/Navigenics-TheScience.pdf (last visited Jan. 09, 2010).
23. 23andMe Store, supra note 19; Navigenics, Inc., Conditions We Cover,
http://www.navigenics.com/visitor/what_we_offer/conditions_we_cover/ (last visited Jan. 09,
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health outcomes across the population by empowering people to act based
on an understanding of their genetic predisposition for certain medical
conditions.”24 This premise is central to the business of DTC personal
genomic companies and it maintains that individuals are not only
empowered by this form of self-knowledge, but that they are also expected
to use their genetic risk profiles in the prevention of disease.25 23andMe
builds on this emerging ethos, but in addition, offers a broader array of
services, including non-medical information, or what the company provides
in its “ancestry edition” product (e.g. tests for genetic lineage and traits such
as wet or dry earwax).26 The success of 23andMe depends in part on
creating a new class of ‘recreational genomics’. Framing it with the
pleasures of hobbies and entertainment, personal genome companies
recast the weighty enterprise of genetic testing for disease—traditionally
overseen by healthcare professionals—into a private matter between the
consumer and the company from which she or he has purchased the
information.27
II. LACK OF CONSENSUS ON DTC GENOMICS
Personal genomics promises to leverage prognostic and predictive tools
toward achieving personalized prevention and treatment of complex
diseases,28 but despite the growing number of risk alleles reported in
genome-wide association studies,29 some scientists are now skeptical about
whether these DNA variants have clinical utility.30 One of the challenges of
genome-wide association studies is the need for improved study designs that
will ensure sufficient power to detect genes of modest risk while minimizing
the potential of false-association signals from the testing of large numbers of
2010); Navigenics, Inc., Our Genetic Testing, http://www.navigenics.com/visitor/what_we_
offer/our_tests/ (last visited Jan. 09, 2010).
24. Navigenics, Inc., Our Mission, http://www.navigenics.com/visitor/about_us/mission
(last visited Jan. 09, 2010).
25. Fred Ledley, A Consumer Charter for Genomic Services, 20 NATURE BIOTECHNOLOGY
767, 767 (2002).
26. See 23andMe, Inc., Ancestry, https://www.23andme.com/ancestry/lineage/ (last
visited Jan. 09, 2010); 23andMe, Inc., Earwax Type – Sample Report, https://www.23and
me.com/health/Earwax-Type/ (last visited Jan. 09, 2010).
27. See Catherine Nash, “Recreational Genetics”, Race and Relatedness, 24
L’OBSERVATOIRE DE LA GENETIQUE 1, 1-7 (2005).
28. See, e.g., Dimitrios H. Roukos et al., Molecular Genetic Tools Shape a Roadmap
Towards a More Accurate Prognostic Prediction and Personalized Management of Cancer, 6
CANCER BIOLOGY & THERAPY 308, 311 (2007) (discussing the use of personalized treatments
for cancer).
29. Pennisi, supra note 1, at 1842-43 (2007) (noting that in 2007 alone, “researchers
linked variants of more than 50 genes to increased risk for a dozen diseases”).
30. See Hunter et al., supra note 3, at 105-106.
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markers.31 Currently, there is a dearth of available sample sets, which has
led to particular problems in the control of factors related to population
substructure and false positive results.32
With genome-wide association studies yielding few definitive results and
many unknowns concerning the contribution of genomic information to
relative risk for complex traits and diseases, several scholars, scientists, and
health professionals have expressed concern that personal genomic
products and services offer little value.33 These concerns have prompted
scholars to suggest that personal genomic information needs to be
interpreted and contextualized by clinicians and counselors in order to be
meaningful to individuals.34 Even when an association between genetic
variation and disease is statistically significant, this does not mean that it is
clinically meaningful.35 “Moreover, simply knowing genetic risks and
disease predispositions may not lead to better health decisions. For some, it
might lead to fatalism and reduced compliance with healthy choices.”36
Some have argued that providing information directly to consumers without
the help of experienced health professionals increases the chance that
consumers will misinterpret their information and apply it inappropriately to
their decisions regarding the management of their health.37 Therefore, the
complexity of the concepts of risk, significance, validity, replication, and
gene/environment interaction increase the likelihood that personal genomic
information may lead to misunderstandings among consumers on how they
should respond to their own results.38
31. See id. at 106.
32. See id.
33. See supra note 3.
34. See, e.g., Gollust et al., supra note 3, at 1764 (noting that consumers may not have
the requisite knowledge to be able to understand the results and limitations of genetic tests).
35. Amy L. McGuire et al., The Future of Personal Genomics, 317 SCIENCE 1687, 1687
(2007).
36. Id. See also Wolfberg, supra note 3, at 545 (citing the chief of the Cancer Genetics
Clinic at Baylor College of Medicine: “My biggest concern is that members of the public are
getting tests that they don’t understand, and their physicians may not understand, and they
may be making big decisions that are ill-informed”).
37. See, e.g., Gail H. Javitt, Policy Implications of Genetic Testing: Not Just for
Geneticists Anymore, 13 ADVANCES CHRONIC KIDNEY DISEASE 178, 179-80 (2006); David
Magnus et al., Genetic-Test Firms Must Follow Law, SAN JOSE MERCURY NEWS, July 11, 2008,
at 19A (noting that individuals can easily allow misinterpretations of their test results influence
their health decisions).
38. See, e.g., Javitt, supra note 37, at 178-79 (noting that genes’ interactions with
environmental factors are largely unknown and that associations between genetic variations
and disease are not necessarily clinically significant); Gollust et al., supra note 3, at 1763-64;
Wasson et al., supra note 8, at 85 (noting throughout the danger that consumers may not
understand their genetic test results and will make inappropriate health choices based upon
erroneous notions).
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Discussion of the ethical and social concerns over the validity and
transparency of DTC genetic tests has focused primarily on products related
to health.39 A body of literature on DTC marketing for breast cancer has
generated calls for increasing scrutiny of corporate practices.40 Several
professional organizations have produced position statements urging for
greater oversight of DTC genetic testing, including the National Society of
Genetic Counselors,41 the International Society of Nurses in Genetics,42 and
the Secretary’s Advisory Committee on Genetics, Health and Society.43 In
January 2007, the American Society of Human Genetics released a
statement on DTC genetic testing in the U.S. urging: 1) greater transparency
regarding information that consumers may require in order to make
informed decisions about genetic testing; 2) increased education of health
personnel regarding the clinical validity of DTC genetic tests; and 3) greater
governmental oversight over both the validity of DTC tests and the use of
commercial information concerning the value and limitations of the DTC
tests.44 The trend in the scientific and bioethics literature seems to be that
the majority of genetic tests currently marketed to the public may not meet
minimum standards for clinical utility.45

39. See, e.g., Gollust et al., supra note 3, at 1762 (specifically focusing only on medical
uses of genetic tests, and avoiding analyses concerning “paternity, identity, genealogy, and
DNA banking”).
40. See, e.g., J. Mouchawar et al., Genetic Testing for Breast and Ovarian Cancer

Susceptibility: Evaluating Direct-to-Consumer Marketing — Atlanta, Denver, Raleigh-Durham,
and Seattle, 2003, 53 MORBIDITY & MORTALITY WKLY. REP. 603, 606 (2004) (arguing that
“[c]ollaboration among public health agencies, health-care providers, the clinical
laboratory/biotechnology industry, and professional organizations” is necessary “as genomics
becomes more integrated into health promotion and disease prevention”).
41. See Position Statement, Nat’l Soc’y of Genetic Counselors, Direct to Consumer
Genetic Testing (2007), http://www.nsgc.org/about/position.cfm.
42. See Position Statement, Int’l Soc’y of Nurses in Genetics, Provision of Quality Genetic
Services and Care: Building a Multidisciplinary, Collaborative Approach Among Genetic
Nurses and Genetic Counselors (Nov. 1, 2006), http://www.isong.org/about/ps_multi
disciplinarygeneticcare.cfm.
43. See Letter from Reed V. Tuckson, Chair, SACGHS, to Tommy G. Thompson, Sec’y of
Health & Human Serv. (Dec. 8, 2004), available at http://oba.od.nih.gov/oba/sacghs/
reports/DTCletter.pdf.
44. Kathy Hudson et al., ASHG Statement on Direct-to-Consumer Genetic Testing in the
United States, 81 AM. J. HUM. GENETICS 635, 636-37 (2007).
45. See, e.g., Javitt, supra note 37, at 178-79 (highlighting the lack of oversight and
transparency, which make it difficult to gauge validity and reliability); Wasson et al., supra
note 8, at 84 (stating that the reliability and validity of DTC genetic tests are difficult to
ascertain); Magnus et al., supra note 37, at 19A (noting that the tests do not take into account
such risk factors as diet, medication, and exercise).
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III. BIOSOCIALITY AND THE SHARING OF PERSONAL GENOMIC INFORMATION
Despite concerns over the utility of personal genomics, DTC personal
genomic companies have expanded their services by essentially claiming
that the public desires direct access to personal genomic information and
that the industry fills that gap by providing expert knowledge and leadership
in research on personalized medicine. This expansion has led to the
development of online sharing tools, collaborations with social networking
platforms, and the creation of online, company-sponsored research
communities. In considering the ethical and regulatory implications of
social networking around personal genomic information, it will be important
to consider not only the benefits (and risks) applicable to individual
consumers as described above, but their impacts on larger social groups
formed by the sharing of personal genomic information.
In its commitment to connecting individuals around genomics, 23andMe
encourages its consumers to share their results with family members, friends,
and others via their website.46 Towards this end, 23andMe has created
online tools allowing its consumers to instantaneously compare their genes
with others who likewise agree to share information.47 This exchange may
occur through one-to-one comparisons or through the establishment of
groups.48 For example, a 23andMe customer may want to connect with a
friend who also has a 23andMe account in order to share their individual
risks for stomach cancer. To do so, she would only need to send a request
to share to her friend using the 23andMe platform, and upon consent, they
may discover that they have a 95.2% similarity in the hundreds of SNPs that
are associated with this disease.49 If the two friends wanted to create a
group of friends with which to share information, they would only need to
make the requests and designate their “friends” as sharers and 23andMe
will provide graphics that will allow them to see the relative percent similarity
or dissimilarity within the group.50
The potential for social networking is amplified through other companyprovided online tools such blogs and dedicated community webpages,
where consumers with similar genomic profiles may congregate in virtual
space to meet and carry on online discussions.51 For example, individuals
who show a higher genetic predisposition to Parkinson’s disease may

46. 23ANDME, INC., GETTING STARTED GUIDE 8 (2008) (noting that members can choose
to share their genomes with other members through 23andMe’s “Genome Sharing”
application).
47. Id.
48. Id. at 12.
49. See id.
50. See id.
51. 23ANDME, INC., supra note 46, at 8-9.
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converse online with others who have received similar information.52 For
example, 23andMe recently announced the organization of their Pregnancy
Community, as seen in Figure 1 below. Suggesting an “instant circle of
friends,” 23andMe creates a dedicated portal for pregnant consumers to
discuss questions they may have about their genetic profiles.53
FIGURE 1. PREGNANCY COMMUNITY: A “CIRCLE OF FRIENDS”

Such online tools provide the infrastructure for new social formations
through a process that has been referred to as “biopolitics.” Biopolitics
describes the use of scientific understanding of life into the field of politics
and governance.54 Historically, this necessitated the inclusion of political
authorities and scientific experts—such as physicians, urban planners, and
others, who could administer, modify, control, and regulate individual
behavior for the collective good.55 The rise of genetics and the emerging
coupling of genetic tests with “wellness programs” and self-care provide a
powerful framework for what some have described as “biological

52. See, e.g., 23andMe, Inc., 23andMe Parkinson’s Community: Strength in Numbers,
https://www.23andme.com/pd/ (last visited Jan. 08, 2010).
53. 23andMe, Inc., Pregnancy Community, https://www.23andme.com/pregnancy/ (last
visited Jan. 09, 2010).
54. MICHEL FOUCAULT, THE HISTORY OF SEXUALITY: VOLUME I: AN INTRODUCTION 139-40
(1978).
55. See id. at 139-41.
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citizenship.”56 This framework merges with the narrative of DTC personal
genomics in that knowing one’s genes and related risk profiles provides the
basis for the modification of behavior and the adoption of preventative
health despite the explicit rejection by the company in its customer
agreements and informed consent forms that its genetic testing products
constitute diagnostic or health-related information.57 By creating virtual
space for individuals to identify and connect through common genomic
information, the company provides the architecture for self-governance of
health that promotes engagement with and management of genomic risk.58
In the emerging era of DTC personal genomics, social networking could
potentially extend beyond any one individual to the creation of biosocial
groups that demand a voice in shaping new genetic technologies. Scholars
have already shown the power of technological developments in creating
collective identity. An example is found in Benedict Anderson’s analysis of
the impact of the printing press in creating “imagined communities” that no
longer tethered groups by geographic proximity, but allowed the idea of
community to be created through shared circuits of information flow.59
Similarly, the Internet and the development of online tools have impacted
the flow of personal genomic information between individual actors.60 This
will require serious consideration of what is at stake for consumers,
companies, and the communities that are forged around the sharing of
personal genomics. Personal genomic information must be understood in a
framework of collective identity in order to identify fundamental ideals and
values that operate in the coalescence of virtual communities. Building on

56. See generally Nikolas Rose & Carlos Novas, Biological Citizenship, in GLOBAL
ASSEMBLAGES: TECHNOLOGY, POLITICS, AND ETHICS AS ANTHROPOLOGICAL PROBLEMS 439, 43958 (Aihwa Ong & Stephen J. Collier, eds., 2005) (describing how scientific and technological
advances are changing the concept of using biology as a classification of citizenship).
57. See 23andMe, Inc., Consent and Legal Agreement [hereinafter 23andMe Legal
Agreement], https://www.23andme.com/about/consent (last visited Jan. 09, 2010) (noting
that “the 23andMe Personal Genome Service is not a test or kit designed to diagnose disease
or medical conditions, and it is not intended to be medical advice”).
58. See 23andMe, Inc., Core Values, https://www.23andme.com/about/values (last
visited Jan. 09, 2010).
59. BENEDICT ANDERSON, IMAGINED COMMUNITIES: REFLECTIONS ON THE ORIGIN AND
SPREAD OF NATIONALISM 54 (rev. ed. 1991).
60. See Matthew R. G. Taylor, Amy Alman & David K. Manchester, Use of the Internet by
Patients and Their Families to Obtain Genetics-Related Information, 76 MAYO CLINIC PROC.
772, 775 (2001) (noting that “[t]he Web for [genetics-related information] provides physicians
and patients equal access to information. Patients and their families can now rapidly and
conveniently access information (and misinformation) about their genetic disorder with the
click of a mouse”).
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Gibbon’s work on the “ethical value of community,”61 questions that probe
the authority, flexibility, and the strategic co-construction of community by
and through DTC genomic companies will be essential in order to fully
consider the impact of the DTC personal genomic market on the trajectory
of genomic medicine.
IV. THE BLURRING BOUNDARY BETWEEN CONSUMER AND RESEARCH PARTICIPANT
The use of social networking tools have been increasingly used by
organizations interested in influencing the course of biomedical research.
For example, in 2004 the non-profit company, PatientsLikeMe, was
launched by three MIT engineers interested in using large-scale online
commercial applications to create communities of patients, health
professionals, and organizations.62 A fundamental goal of the company
was to provide patients access to others who could provide information and
share experiences about specific diseases of interest.63 Under the motto of
“patients helping patients live better everyday,”64 the online site provides
infrastructure for virtual communities organized around a broad range of
diseases and conditions, including amyotrophic lateral sclerosis (ALS),
Undergirding
HIV/AIDS, and post-traumatic stress disorder.65
PatientsLikeMe’s approach is an “Openness Philosophy,” that emphasizes
that “openness is a good thing.”66 Asserting that transparency is critical for
the greater good, the company states that “the Internet can democratize
patient data and accelerate research like never before. Furthermore, we
believe data belongs to you the patient to share with other patients,
caregivers, physicians, researchers, pharmaceutical and medical device
companies, and anyone else that can help make patients’ lives better.”67
Echoing a similar goal to “dramatically accelerate the pace of genetics
research,” 23andMe unveiled its new research arm, 23andWe in the spring

61. See Sahra Gibbon, Community, the Commons and Commerce: the Ownership of
BRCA Genes and Genetic Testing, in CONTESTING MORALITIES: SCIENCE, IDENTITY, CONFLICT
43, 54 (Nanneke Redclift ed., 2005) (analyzing the use of “moral communities” in a
discussion of commercial genetic testing in the UK).
62. PatientsLikeMe.com, About Us, http://www.patientslikeme.com/about (last visited Jan.
09, 2010).
63. Id.
64. Id.
65. PatientsLikeMe.com, Home Page, http://www.patientslikeme.com/ (last visited Jan.
09, 2010).
66. PatientsLikeMe.com, Openness Philosophy, http://www.patientslikeme.com/about/
openness (last visited Jan. 09, 2010).
67. Id.
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of 2008.68 This program focuses on the company’s well-publicized goal to
actively engage with consumers who wish to participate in population-based
genetic research. Stating that “23andMe isn’t just about you,” the company
explains that 23andWe “gives customers the opportunity to leverage their
data by contributing it to studies of genetics.”69 The company states that
“[w]ith enough data [it] can produce revolutionary findings that will benefit
us all.”70
In Figure 2 below, 23andMe highlights a personalized page which
contains an individual’s genetic data in the context of muscle
performance.71 Describing what the company identifies as gene ACTN3,
the page describes how variation in the presence or absence of this SNP
may contribute to whether a customer is more likely to be a sprinter or
marathoner.72 With an account, the customer is able to see his own data in
comparison with the “23andWe Community,” as indicated in the inset box
titled with the query, “Tortoise or Hare?”73
When signing up for 23andMe services, consumers are informed that
their samples will become part of an anonymized database controlled by the
company.74 To participate in the 23andWe community, consumers are
asked to sign up.75 Consenting consumers are able to share their results
with others and may be asked to participate in studies sponsored in
collaboration with various researchers through collaborative relationships
between 23andMe and other institutions and organizations.76

68. Press Release, 23andMe, Inc., “23andWe” Mission: To Dramatically Accelerate the
Pace of Genetics Research, (May 29, 2008), available at https://www.23andme.com/about/
press/20080529/.
69. 23andMe, Inc., 23andWe Research [hereinafter 23andWe Research], https://www.23
andme.com/research (last visited Jan. 09, 2010).
70. Id.
71. 23andMe, Inc., Muscle Performance—Sample Report, https://www.23andme.com/
health/Muscle-Performance/ (last visited Jan. 09, 2010).
72. Id.
73. 23andWe Research, supra note 69 (from Research page, click on “view slideshow”;
go to slide number 5).
74. See 23andMe Legal Agreement, supra note 57.
75. See 23andWe Research, supra note 69.
76. 23andMe Legal Agreement, supra note 57.
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FIGURE 2. 23ANDWE PARADIGM FOR GENOMIC RESEARCH

Although the DTC personal genome companies emphasize that genetic
data collected will never be sold, several have said they might consider
partnerships with academic researchers or nonprofit drug developers in the
future as a way of recruiting subjects for clinical trials and collecting
additional information for research.
For example, 23andWe and
PatientsLikeMe have announced a collaboration focused on research on
Parkinson’s Disease through which PatientsLikeMe will recruit individuals to
be genotyped by 23andMe and then participate in company-sponsored
research.77 23andMe even has its own Facebook page.78 Such social
networking opportunities allow for instantaneous and pervasive sharing of
personal genomic information in the course of routine, day-to-day
socializing practices and demands research on the possible implications of
these new social circuits.

77. See Press Release, PatientsLikeMe.com, PatientsLikeMeTeams Up With 23andMe to
Help Parkinson’s Patients (June 9, 2009), http://www.patientslikeme.com/press/20090609/
17-patientslikeme-teams-up-with-23andme-to-help-parkinsons-patients?disease_tag=hiv.
78. Facebook, 23andMe, http://www.facebook.com/23andMe?v=info (last visited Jan.
09, 2010).
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The coalescence of consumer groups around genomic information and
disease is an emerging trend. Over the last several decades advocacy
groups have proliferated79 and provided critical funding for biomedical
research. With the help of the Internet, public advocacy groups have
created relationships with scientists and clinicians that have had a direct
impact on the trajectory of research80 by providing greater input in research
questions and design, recruiting participants, and catalyzing studies
responsive to patient experiences and needs.81 These patient groups have
produced what some scholars have identified as “new forms of democratic
participation.”82
However, as the relationship between patient groups and industry
partners has become more intertwined in recent years, there is concern over
potential conflicts of interest. Stating the need for oversight, some have
cautioned against adopting valueless or even harmful products or
interventions that are promoted by industry through the use of patient
voices.83 In a context of population-based genomic research and the

79. See, e.g., Amy Dockser Marcus, Advocacy Overload? Activists Seek to Unify Efforts of
Groups Targeting Diseases; A Brain-Tumor Collaborative, WALL ST. J., Oct. 10, 2006, at D1
(noting that for brain tumors, there are 141 different patient-advocacy groups for the 43,000
new diagnoses each year. That means there is roughly one advocacy group for every 305
new patients diagnosed with primary brain tumors).
80. See generally NIKOLAS ROSE, THE POLITICS OF LIFE ITSELF: BIOMEDICINE, POWER, AND
SUBJECTIVITY IN THE TWENTY-FIRST CENTURY 148 (2007) (noting that today’s patient
organizations are not simply focused on increased funding, but on actively “shaping the
direction of science”); Sharon F. Terry et al., Advocacy Groups as Research Organizations:
The PXE International Example, 8 NATURE REVIEWS GENETICS 157, 157-58 (2007) (noting that
advocacy organizations are becoming more involved in research by becoming more active in
areas like translational research); Nancy Tomes, The Patient as a Policy Factor: A Historical
Case Study of the Consumer/Survivor Movement in Mental Health, 25 HEALTH AFF. 720, 720,
724 (2006) (analyzing the importance of consumer/survivor groups in the area of mental
health); John W. Walsh et al., A Review of the Alpha-1 Foundation: Its Formation, Impact,
and Critical Success Factors, 51 RESPIRATORY CARE 526, 526, 530 (2006) (discussing one
specific patient advocacy organization and its influence on research and clinical care for its
targeted community).
81. See Laura Landro, The Growing Clout of Online Patient Groups, WALL ST. J., June
13, 2007, at D1. See also Jean Cohen, The Role of Patients’ Associations in Assisted
Reproduction Treatment, 13 REPROD. BIOMED. ONLINE 447, 447-48 (2006).
82. Deborah Heath, Rayna Rapp & Karen-Sue Taussig, Genetic Citizenship, in A
COMPANION TO THE ANTHROPOLOGY OF POLITICS 152 (David Nugent & Joan Vincent eds.,
2004).
83. See Ezekiel J. Emanuel, Drug Addiction: Cancer in the Courts, NEW REPUBLIC 9, 9-12
(2006) (discussing how allowing access to unproven treatments provides false hope to
terminally ill patients).
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ongoing challenges of recruitment of individuals into studies,84 models of
openness through social networking, as evident in companies like 23andMe
and PatientsLikeMe, demand careful consideration. These conflicts are not
addressed in the current arena of DTC personal genomics.
In the summer of 2009, 23andMe built on their efforts of 23andWe by
unveiling a new program entitled, “The 23andMe Research Revolution.”85
The Research Revolution initiative is aimed at enrolling 1,000 consumers
into ten studies that focus on the following diseases and conditions:
migraines, psoriasis, rheumatoid arthritis, severe food allergies, celiac
disease, lymphoma and leukemia, multiple sclerosis, amyotrophic lateral
sclerosis (ALS), epilepsy, and testicular cancer.86 At a discounted rate of
$99, consumers receive most of the genetic information on diseases and
traits entitled to full price customers—except for ancestry information—and
are able to share information using the company web site.87 Also, unlike
customers paying the $399 price, Research Revolution participants do not
have access to their raw genetic data.88 As Figure 3 below from the
Research Revolution webpage illustrates, customers are asked to take
surveys that ask questions about lifestyle and behavior.89 Rooting this
product firmly in future societal benefit, 23andMe states that participating
“could lead to better healthcare for everyone.”90 A challenge for DTC
genomic research activities is the incongruous position of companies in that
the genetic information they are providing is not “medical” or “health
related,” and yet, the same information is used as the basis for galvanizing
the consumer base to participate in medical research.

84. See, e.g., Mark A. Hall, et al., Concerns in a Primary Care Population about Genetic
Discrimination by Insurers, 7 GENETICS MED. 311 (2005) (analyzing public concerns about
genetic discrimination and its influence on research participation).
85. 23andMe, Inc., The 23andMe Research Revolution Overview [hereinafter 23andMe
Research Revolution Overview], https://www.23andme.com/researchrevolution/overview/ (last
visited Jan. 09, 2009).
86. 23andMe, Inc., The 23andMe Research Revolution, https://www.23andme.com/
researchrevolution/ (last visited Jan. 09, 2010).
87. 23andMe, Inc., Compare Services, https://www.23andme.com/researchrevolution/
compare/ (last visited Jan. 09, 2010).
88. Id.
89. See 23andMe Research Revolution Overview, supra note 85.
90. Id. (go to Overview page; click on “view slideshow”; go to slide 7, The Benefits of
Participating in 23andMe Research).
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FIGURE 3. “RACE TO 1000”

An important ethical question prompted by these new formations is
whether DTC genomic consumers may also be considered research
subjects. If so, the next question is whether companies must fulfill the same
responsibilities and obligations to their consumers as would be expected in
traditional contexts of genomic research. Are consumers ongoing vested
partners in the research activities of 23andMe or are they “altruists,” who
are donating their samples and genetic data for the potential benefit of
general knowledge? What type of assurances are there that the anonymity
of genetic information will be safeguarded against genetic technologies
aimed at identifying increasingly specific genetic variation where individual
identity may be inferred even when personal information has been de-linked
from samples? What obligations does the company have to its consumers
to inform them of the type of research being conducted using consumer
samples?
Research now indicates that individual SNP profiles can be identified
within pooled datasets.91 Homer et al. analyzed complex mixes of genomic
DNA using high-density SNP genotyping microarrays.92 This allowed them
to accurately identify individuals from aggregated genetic data, leading
them to conclude that individuals can be identified in de-identified datasets
91. Nils Homer et al., Resolving Individuals Contributing Trace Amounts of DNA to Highly
Complex Mixtures Using High-Density SNP Genotyping Microarrays, 4 PLOS GENETICS 1, 1-2
(2008), available at http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.
pgen.1000167.
92. Id. at 1.
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of more than 1,000 people.93 In response, the NIH and other institutions,
including the Wellcome Trust Case Control Consortium in England and the
Broad Institute of MIT and Harvard in Boston, removed previously publicly
available aggregated data and have established a use policy that requires
the protection of individual identity.94 Such developments are salient to the
creation of DTC personal genomics where DNA datasets may be distributed
for genomic research. Ethical and social concerns over the security and
confidentiality of personal information volunteered by consumers require
greater scrutiny in order to ensure that consumers’ genetic information is
protected when it is shared for research.
V. THE NEED FOR EMPIRICAL RESEARCH
Despite the proliferation of companies that seek to bring personal
genomic services and products to market, there is little consensus in the
scientific literature over the clinical utility of many of the genome-wide study
results published thus far. However, it is also evident that the once
seemingly elusive $1000 genome will be a reality in the near future and that
routine whole genome sequencing may soon be ubiquitous. How meaning
will be inferred to this abundance of personal genetic information and in
what manner it will be understood will be critical to how genomic
information becomes integrated into healthcare and social relationships. A
serious challenge to efforts to fully understand the ethical and social
implications of DTC personal genomics is a critical gap in empirical
research on the perspectives and practices of two important stakeholder
groups: the companies who provide genetic ancestry products and the
individuals who consume them.
A 2007 study by Goddard et al., assessed consumer and physician
awareness of genomic tests and consumer use of such tests via two national
surveys.95 They found that consumers who were aware of the tests tended to
be young and educated with a high income.96 Given the costs of personal
genomic tests, it would seem that the test results reflect the population that
would be the most likely to purchase the tests. However, as yet, there has
been little research that reveals much more of who really are the consumers
of DTC personal genomics tests. Studies that investigate not only who DTC
personal genomic consumers are and perhaps more importantly, how
individuals interpret and utilize their personal genomic information in daily
decisions and everyday practice, will be essential.
93. Id. at 2.
94. NAT’L INST. OF HEALTH, NIH BACKGROUND FACT SHEET ON GWAS POLICY UPDATE 1-2
(2008), http://grants.nih.gov/grants/gwas/background_fact_sheet_20080828.pdf.
95. Goddard et al., supra note 2 at 511.
96. Id. at 513.
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As social networking through online tools and platforms expands, it will
be important to assess how consumers might be protected against potential
discriminatory use of personal genomic information. In 2008, Congress
passed the Genetic Information Nondiscrimination Act (GINA), which offers
broad protections against genetic discrimination in the provision of health
insurance and decisions regarding employment.97 Although this statute fills
an important and long-standing gap in legal protections against genetic
discrimination, there remain several limitations to the legislation. Such
limitations include cases where genetic information is obtained “through
publicly-available information” or it is “inadvertently obtained” through
general searches on the internet.98
Focusing on genetic information as the unit of analysis, an examination
of the life-course of personal genomic information as it is shared with family
members, health professionals, online communities, and researchers, will
illuminate the impact of DTC personal genomics on the current regulatory
landscape. Questions that will be important to address are: Who are the
people who are using online tools and platforms to share their personal
genomic information, and what genetic information is being shared? What
impact does sharing information have on the behaviors and decisions of
primary and secondary actors? What are the similarities and differences
among individuals who share their information and those who volunteer to
participate in DTC-sponsored research efforts?
Detailed analyses
concerning how personal genomic information “travels” to different
individuals and institutions through the web will be important in creating
regulatory safeguards against potential abuse.
Another important area of research will be to investigate the prevailing
assumptions that have ushered in this new era of personal genomics and
served as rationale for emerging markets. Key questions will be to
interrogate what “democratization of the genome” means for healthcare
and what will be the future of large-scale population-based genetic
research? Such a study would contribute a more informed assessment of
the rights and responsibilities of companies and consumers who enter into
research relationships. It will help contribute to the understanding of how
regulations can address the broader ethical implications of consumer
participation in DTC-sponsored research communities, and also explore the
long-term significance of DTC genetic testing for the larger landscape of
genomic medical research.

97. Genetic Information Nondiscrimination Act of 2008 (GINA), Pub. L. No. 110-233,
122 Stat. 881 (2008) (to be codified at 42 U.S.C. 2000ff et. seq. in scattered sections of 26
U.S.C., 29 U.S.C., and 42 U.S.C.).
98. § 202-205. See also Regulations Under the Genetic Information Nondiscrimination
Act of 2008, 74 Fed. Reg. 9056, 9063 (proposed Mar. 2, 2009).
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In an era of increasingly efficient genotyping technologies, DTC
genomic companies have emerged as new regimes of biosociality where
personal genetic information may reconstitute human identity and create
new networks of social relationships. Personal genetic information and the
practice of comparing one’s own profile to others has the potential to create
biosocial groups that ultimately serve to overcome the “nature/culture split”
where biology becomes inherent to both our social identities and our
positions in the world.99 As personal genomic information is used in novel
ways, it will be critical to put in place effective safeguards and policies.
Successful translation of personal genomic information will depend on the
adaptability of current models towards ethical oversight in considering new
commercial, clinical, and research trajectories of the personal genome era.

99. Paul Rabinow, Artificiality and Enlightenment: From Sociobiology to Biosociality, in
INCORPORATIONS, 234, 241-44 (Jonathan Crary & Sanford Kwinter eds., 1992).
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